Ivosidenib, a therapeutic drug for acute myeloid leukemia (AML) targeting specific gene mutations, has long been a focus of attention among patients and the medical community regarding its price. So, what is the price of Ivosidenib?
What is the price of Ivosidenib?
The price of Ivosidenib varies depending on the manufacturer, specifications, and market supply. Currently, the main commercially available Ivosidenib is produced by Lucius (Laos). For the specification of 250mg × 60 tablets produced by Lucius (Laos), the price is approximately 604 US dollars per box.
Indications of Ivosidenib
Ivosidenib is a targeted drug used to treat specific types of leukemia. The following is a detailed breakdown of its indications:
Relapsed or Refractory Acute Myeloid Leukemia (AML)
It is indicated for adult patients with relapsed or refractory acute myeloid leukemia who are diagnosed with a susceptible IDH1 mutation using a fully validated detection method. Ivosidenib can reduce the white blood cell count in these patients, decrease the enlargement of the spleen and lymph nodes, and improve patients' pancytopenia or cell survival quality.
Newly Diagnosed Acute Myeloid Leukemia
When combined with azacitidine, it is used for newly diagnosed acute myeloid leukemia patients with a susceptible IDH1 mutation. The combination of Ivosidenib and azacitidine provides a new treatment option for such patients, especially when they cannot tolerate intensive induction chemotherapy.
Ivosidenib is a targeted drug for diseases caused by IDH1 mutations, and it has shown good efficacy in the treatment of relapsed or refractory acute myeloid leukemia, newly diagnosed acute myeloid leukemia under specific conditions, and locally advanced or metastatic cholangiocarcinoma. In the future, with the advancement of clinical trials and the continuous expansion of its indications, Ivosidenib is expected to bring benefits to more patients.
Efficacy of Ivosidenib
Ivosidenib is a targeted drug for isocitrate dehydrogenase-1 (IDH1) mutations and has demonstrated good efficacy in clinical treatment. The following is a detailed analysis of its efficacy:
Clinical Response Rate
Ivosidenib has shown a high clinical response rate in clinical trials. For AML patients with IDH1 mutations receiving Ivosidenib treatment, a considerable number of patients have experienced disease remission, including complete remission and partial remission.
Prolonged Survival
Compared with traditional chemotherapy or other treatment regimens, Ivosidenib can prolong patients' progression-free survival (PFS) and overall survival (OS). This means that after receiving Ivosidenib treatment, the time to disease progression is delayed for patients, and their overall survival time is extended.
The efficacy of Ivosidenib may vary depending on individual patient differences, disease status, and treatment regimens. When using Ivosidenib for treatment, patients should strictly follow the doctor's guidance and undergo regular monitoring of disease changes to evaluate the efficacy. Patients should also actively cooperate with treatment, maintain a positive mindset and healthy living habits to improve treatment outcomes and quality of life.
